Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis
暂无分享,去创建一个
Martin C. Müller | C. Haferlach | A. Reiter | N. Cross | P. Erben | C. Walz | J. Score | A. Hochhaus | G. Metzgeroth | T. Ernst | D. Gosenca | J. Reinhard | F. del Valle | Jürgen Mix
[1] R. Yeh,et al. The molecular anatomy of the FIP1L1-PDGFRA fusion gene , 2009, Leukemia.
[2] A. Jones,et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions , 2009, Leukemia.
[3] C. Haferlach,et al. Identification of a MYO18A‐PDGFRB fusion gene in an eosinophilia‐associated atypical myeloproliferative neoplasm with a t(5;17)(q33‐34;q11.2) , 2009, Genes, chromosomes & cancer.
[4] S. Schnittger,et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study , 2008, British journal of haematology.
[5] A. Tefferi. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1 , 2008, Journal of cellular and molecular medicine.
[6] R. A. Etten,et al. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders , 2008, Leukemia.
[7] D. Oscier,et al. The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre‐mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1 , 2008, Genes, chromosomes & cancer.
[8] M. Baccarani,et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study , 2007, Haematologica.
[9] A. Reiter,et al. Two novel imatinib‐responsive PDGFRA fusion genes in chronic eosinophilic leukaemia , 2007, British journal of haematology.
[10] M. Rondoni,et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.
[11] N. Schmitz,et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma , 2007, Leukemia.
[12] C. Haferlach,et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. , 2007, Haematologica.
[13] A. Reiter,et al. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. , 2007, Current drug targets.
[14] Y. Arima,et al. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. , 2006, International journal of oncology.
[15] T. Haferlach,et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2‐PDGFRA fusion gene , 2006, Genes, chromosomes & cancer.
[16] D. Birnbaum,et al. t(5;12)(q23–31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera , 2006, Leukemia.
[17] F. Grand,et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia , 2006, Leukemia.
[18] R. Lührmann,et al. Human U4/U6 snRNP Recycling Factor p110: Mutational Analysis Reveals the Function of the Tetratricopeptide Repeat Domain in Recycling , 2004, Molecular and Cellular Biology.
[19] J. Kutok,et al. Positive and negative regulatory roles of the WW-like domain in TEL-PDGFbetaR transformation. , 2004, Blood.
[20] P. Paschka,et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C , 2003, Leukemia.
[21] M. Slovak,et al. Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. , 2003, Human pathology.
[22] J. Gabert,et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.
[23] Peter Marynen,et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.
[24] D. DiMaio,et al. Definition of an Inhibitory Juxtamembrane WW-like Domain in the Platelet-derived Growth Factor β Receptor* , 2002, The Journal of Biological Chemistry.
[25] B. Bain,et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.
[26] A. Bindereif,et al. p110, a novel human U6 snRNP protein and U4/U6 snRNP recycling factor , 2002, The EMBO journal.
[27] Nicholas C P Cross,et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. , 2002, Human molecular genetics.
[28] K. Shirouzu,et al. Expression of tumor rejection antigens in colorectal carcinomas , 2002, Cancer.
[29] P. Marynen,et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). , 2002, Blood.
[30] J. Kutok,et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). , 2001, Blood.
[31] T. Koga,et al. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients , 2001, British Journal of Cancer.
[32] S. Kulkarni,et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). , 2000, Cancer research.
[33] N Asou,et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13) , 1999, Genes, chromosomes & cancer.
[34] Todd R. Golub,et al. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.
[35] G. Saglio,et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories , 2008, Leukemia.
[36] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[37] J. Melo,et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. , 2007, Blood.
[38] J. Melo,et al. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. , 1994, Leukemia.
[39] N. Nomura,et al. Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1. , 1994, DNA research : an international journal for rapid publication of reports on genes and genomes.